期刊
SEXUALLY TRANSMITTED DISEASES
卷 37, 期 3, 页码 197-203出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/OLQ.0b013e3181bf542c
关键词
-
资金
- American Cancer Society [MSRG-06-259-01-CPPB]
- National Cancer Institute [R25 CA57726]
- Investigator-Initiated Studies Program of Merck and Co., Inc.
- Merck and Co., Inc.
- GlaxoSmithKline (GSK)
Objective: Due to higher rates of human papillomavirus (HPV) infection and anal cancer among gay and bisexual men, we aimed to characterize their willingness to get HPV vaccine and identify correlates of vaccine acceptability. Methods: We surveyed a national sample of men aged 18 to 59 who self-identified as either gay (n = 236) or bisexual (n = 70) during January 2009. We analyzed data using multivariate logistic regression. Results: Most men had heard of HPV vaccine (73%, 224/306) and were willing to get it (74%, 225/306). HPV vaccine acceptability was higher among men who believed their doctor would recommend getting the vaccine (OR = 12.87, 95% CI: 4.63-35.79) and those who were unsure (OR = 3.15, 95% CI: 1.47-6.76), as compared to men who believed their doctor would not recommend it. Acceptability was also higher among men who reported 5 or more lifetime sexual partners (OR = 3.39, 95% CI: 1.34-8.55), perceived greater severity of HPV-related disease (OR = 1.92, 95% CI: 1.18-3.14), perceived higher levels of HPV vaccine effectiveness (OR = 1.97, 95% CI: 1.27-3.06), or reported higher levels of anticipated regret if they did not get vaccinated and later developed an HPV infection (OR = 2.39, 95% CI: 1.57-3.61). Conclusions: HPV vaccine acceptability was high among gay and bisexual men. These findings identify potentially important beliefs and attitudes for future communication efforts about HPV and HPV vaccine among gay and bisexual men.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据